Safety and monitoring for patients receiving Molnupiravir for COVID-19



SAFETY AND GENERAL MONITORING

Prior to starting molnupiravir

If clinically indicated, evaluate for pregnancy. If pregnant, the patient should not be treated with Molnupiravir.

During treatment

Advise patients taking molnupiravir to monitor for any side-effects.

DRUG INTERACTIONS AND ADVERSE EFFECTS

Drug interactions

No drug-drug interactions have been identified, based on limited data available.

Adverse effects

- Common side-effects include diarrhoea, nausea, dizziness, headache.
- Uncommon side-effects include vomiting, rash, hives.
- Severe hypersensitivity reactions, including anaphylaxis, have been reported with molnupiravir and are extremely rare. If such reactions occur instruct patient to seek immediate care.
- Embryo-fetal toxicity

Antiviral resistance

- Data is currently insufficient to ascertain how high the barrier of resistance is with SARS-CoV-2 to molnupiravir. Based on experience with other similar types of antivirals, the drug will place a selective pressure for resistance mutations within individuals, with the potential to spread to the population.
- Non-clinical and/or clinical data are needed.

https://app.magicapp.org/#/guideline/nBkO1E/section/LqlGN4

REPORTING OF ADVERSE EVENTS IN PHARMACOVIGILANCE PROGRAMMES

- Molnupiravir is a new drug and there is limited safety data currently available.
- Patients should be advised to enroll in and report adverse events to local pharmacovigilance programmes. These programmes are intended to recognize side-effects and potential harms not detected in clinical trials.
- A WHO study protocol is now available for use: Safety monitoring of molnupiravir for treatment of mild to moderate COVID-19 infection in low- and middle-income countries using cohort event monitoring: a WHO study.



For detailed information see Safety monitoring for molnupiravir: WHO study protocol

Remember the **FIVE RIGHTS** of drug administration:



Disclaimer:

Decisions regarding the use of any medication must be made by a licensed health provider and take into account each patient's specific clinical history and other circumstances, and be in accordance with relevant local management and prescribing guidelines.





For detailed information, see WHO Therapeutics and COVID-19: living guideline. https://www.who.int/teams/health-carereadiness-clinical-unit/covid-19/therapeutics

